Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ashley

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
The Journal of Clinical Investigation|April 17, 2025
Disruption of Ataxia-telangiectasia mutated kinase enhances radiation therapy efficacy in spatially-directed diffuse midline glioma modelsAvani Mangoli, Vennesa Valentine, Spencer Maingi, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Scientific Reports|October 23, 2025
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in gliomaKirit Singh, Matthew W Foster, Marlene J Violette, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncogenic drivers shape the tumor microenvironment in human gliomasBo Zhao, Chae Yun Cho, Lingqun Ye, et al.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature Medicine|February 27, 2025
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastomaGeorgina V Long, Elena Shklovskaya, Laveniya Satgunaseelan, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Cancer Immunology Research|April 4, 2024
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer ImmunotherapyMichael V Martin, Salvador Aguilar-Rosas, Katka Franke, et al.
Nature Communications|February 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathwaysMark W Youngblood, Shashwat Tripathi, Hinda Najem, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Investigation|April 17, 2025
Disruption of Ataxia-telangiectasia mutated kinase enhances radiation therapy efficacy in spatially-directed diffuse midline glioma modelsAvani Mangoli, Vennesa Valentine, Spencer Maingi, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Scientific Reports|October 23, 2025
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in gliomaKirit Singh, Matthew W Foster, Marlene J Violette, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncogenic drivers shape the tumor microenvironment in human gliomasBo Zhao, Chae Yun Cho, Lingqun Ye, et al.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature Medicine|February 27, 2025
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastomaGeorgina V Long, Elena Shklovskaya, Laveniya Satgunaseelan, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Cancer Immunology Research|April 4, 2024
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer ImmunotherapyMichael V Martin, Salvador Aguilar-Rosas, Katka Franke, et al.
Nature Communications|February 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathwaysMark W Youngblood, Shashwat Tripathi, Hinda Najem, et al.
Pageof 13